🔍

SYNGENE - Syngene Intl.

📊 NSE: SYNGENE 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 14:03

📢 Recent Corporate Announcements

Syngene: Tax Penalty Proceedings Dropped for AY 2018-19 Involving Rs 2.78 Crore

🟢 POSITIVE ⭐ 4/10

LEGAL 📅 14 Mar 2026, 06:53 PM

Syngene International has received a favorable order from the National Faceless Assessment Centre regarding Assessment Year 2018-19. The authority has dropped penalty proceedings that were originally initiated in March 2023 following a disallowance of expenses worth Rs 2.78 crore. This follows a previous appellate order where the company was granted relief on the full disallowed amount. The company confirms there will be no material financial impact on its operations or activities due to this development.

National Faceless Assessment Centre dropped penalty proceedings for AY 2018-19.
The proceedings were related to a previous disallowance of expenses totaling Rs 2,78,45,669.
The company had already secured relief for the full amount of Rs 2.78 crore in September 2025.
The current order confirms no penalty, restrictions, or sanctions will be imposed on the company.

💡 This is a routine resolution of a tax dispute; investors should view this as a positive administrative clearance. No specific action is required as there is no material financial impact.

Syngene International to Meet Alquity Investment Management on March 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 03:38 PM

Syngene International Limited has scheduled a one-on-one virtual meeting with Alquity Investment Management on March 18, 2026, at 4:00 PM IST. This disclosure is part of the company's regular investor relations engagement under SEBI Regulation 30. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the discussion. Such meetings are standard practice for listed companies to interact with institutional investors regarding publicly available information.

One-on-one virtual meeting scheduled with Alquity Investment Management.
The meeting is set for March 18, 2026, at 4:00 PM IST.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
The notification was officially filed with BSE and NSE on March 13, 2026.

💡 No immediate action is required as this is a routine investor interaction. Investors may check the company's website later for any presentation materials or transcripts shared during the meeting.

Syngene Schedules One-on-One Virtual Meeting with Multi-Act Equity on March 16

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Mar 2026, 06:42 PM

Syngene International Limited has scheduled a virtual one-on-one meeting with Multi-Act Equity Consultancy Pvt. Ltd. The meeting is slated for March 16, 2026, at 11:00 AM IST. This disclosure is a routine requirement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the session.

One-on-one virtual meeting scheduled with Multi-Act Equity Consultancy Pvt. Ltd
Meeting date set for March 16, 2026, at 11:00 AM IST
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed
The notification was filed with stock exchanges on March 11, 2026

💡 No immediate action is required as this is a routine investor relations activity. Investors may check the company website later for any presentation materials or transcripts related to the meeting.

Syngene Announces Major Leadership Reshuffle; New CCO and CHRO Appointed

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 06 Mar 2026, 04:04 PM

Syngene International has announced a significant restructuring of its senior management team, effective May 1, 2026. Three key executives, including the Interim Chief Commercial Officer, Chief Human Resources Officer, and Head of SynVent, will depart the company by mutual consent on April 30, 2026. To ensure continuity, the company has appointed Mr. Abhijit Zutshi, a Biocon veteran with over 20 years of experience, as the new CCO. Ms. Maninder Singh Puri, who has over 25 years of HR leadership experience, will join as the new CHRO.

Departure of 3 senior management personnel including Interim CCO Caroline Hempstead and CHRO Andrew Webster on April 30, 2026.
Appointment of Abhijit Zutshi as CCO, leveraging his 20+ years of commercial and global generics experience at Biocon.
Appointment of Maninder Singh Puri as CHRO, bringing 25 years of experience from firms like Accenture and Biocon Generics.
Dr. Kenneth Barr, Head of SynVent and Strategic Collaborations, will also be exiting the company by mutual consent.
All leadership transitions are scheduled to be completed by May 1, 2026, to ensure organizational continuity.

💡 Investors should monitor the transition period for any potential disruption in commercial execution, although the appointment of experienced group veterans from Biocon is a stabilizing factor.

Syngene International to Meet Tata MF on February 25, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 04:23 PM

Syngene International Limited has scheduled a one-on-one physical meeting with Tata Mutual Fund. The meeting is slated for February 25, 2026, at 3:15 PM IST in Bengaluru. This disclosure is a routine filing under Regulation 30 of SEBI Listing Obligations. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during this interaction.

One-on-one physical meeting scheduled with Tata MF on February 25, 2026
Meeting venue is set for Bengaluru at 3:15 PM IST
Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015
Company confirmed that no unpublished price sensitive information will be disclosed

💡 This is a routine investor engagement and requires no immediate action. Investors may look for any subsequent presentation or transcript if the company chooses to publish one on its website.

Syngene Receives Favorable Tax Appeal Orders for AY 2015-16, 2018-19, and 2021-22

🟢 POSITIVE ⭐ 6/10

LEGAL 📅 18 Feb 2026, 04:50 PM

Syngene International has received favorable orders from the National Faceless Appeal Centre (NFAC) regarding tax appeals for the assessment years 2015-16, 2018-19, and 2021-22. The NFAC has partially allowed relief to the company against previous tax additions and disallowances. Consequently, the company expects a reduction in its contingent liabilities and is likely eligible for tax refunds. No penalties or sanctions have been imposed, and the company does not foresee any material negative impact on its operations.

NFAC passed orders for AY 2015-16, 2018-19, and 2021-22, partially allowing the company's appeals against previous tax disallowances.
The company expects a reduction in contingent liabilities and eligibility for tax refunds following these orders.
No penalties, restrictions, or sanctions were imposed by the authority in the orders received in February 2026.
The Assessing Officer will now pass a consequential order to give effect to the NFAC's decision.

💡 Investors should view this as a positive development that reduces long-term tax uncertainty and improves the balance sheet by lowering contingent liabilities. No immediate action is required as the company is still analyzing the final financial impact of the orders.

Syngene Receives Favorable Tax Appeal Orders for AY 2013-14, 2014-15, and 2017-18

🟢 POSITIVE ⭐ 6/10

LEGAL 📅 14 Feb 2026, 09:17 PM

Syngene International has received orders from the National Faceless Appeal Centre (NFAC) regarding tax disputes for three assessment years: 2013-14, 2014-15, and 2017-18. The NFAC has partially allowed the company's appeals against previous tax additions and disallowances made by the Assessing Officer. Consequently, the company expects a reduction in its contingent liabilities and is now eligible for a tax refund. While the exact monetary impact is yet to be quantified by the Assessing Officer, the management does not expect any material negative impact on financials.

NFAC passed orders on February 13, 2026, partially allowing appeals for AY 2013-14, 2014-15, and 2017-18.
The company expects a reduction in contingent liabilities following the favorable ruling.
Syngene is now eligible for a tax refund once the Assessing Officer passes the final order giving effect to the NFAC ruling.
No penalties, restrictions, or sanctions were imposed in the current orders.

💡 This is a positive development as it resolves long-standing tax disputes and strengthens the balance sheet by reducing contingent liabilities. Investors should monitor future disclosures for the exact refund amount once the final assessment order is passed.

Syngene Receives Favorable Tax Appeal Orders for Multiple Assessment Years

🟢 POSITIVE ⭐ 6/10

LEGAL 📅 14 Feb 2026, 09:14 PM

Syngene International has received orders from the National Faceless Appeal Centre (NFAC) regarding tax appeals for Assessment Years 2013-14, 2014-15, and 2017-18. The NFAC has partially allowed the company's appeals against previous tax additions and disallowances made by the Assessing Officer. This outcome is expected to result in a reduction of the company's contingent liabilities and eligibility for tax refunds. While the company states there is no material impact on current financials, the resolution of these long-standing disputes provides better financial clarity.

NFAC orders dated February 13, 2026, provide partial relief for AY 2013-14, 2014-15, and 2017-18
Company expects a reduction in contingent liabilities and is now eligible for tax refunds
The Assessing Officer is required to pass a final order to give effect to the NFAC's decision
No penalties, restrictions, or sanctions were imposed on the company in these proceedings

💡 The resolution of these tax disputes is a positive development that reduces potential liabilities and may lead to cash inflows via refunds. Investors should monitor future filings for the specific refund amounts once the Assessing Officer passes the final order.

Syngene Receives Favorable Tax Order from NFAC for AY 2012-13 Relief

🟢 POSITIVE ⭐ 4/10

LEGAL 📅 14 Feb 2026, 09:11 PM

Syngene International has received a favorable order from the National Faceless Appeal Centre (NFAC) regarding a tax dispute for Assessment Year 2012-13. The order directs the Assessing Officer to verify specific details and grant relief to the company against a previous disallowance of certain expenses made in December 2019. While the final financial impact will be determined after the Assessing Officer's verification, the company currently anticipates no material impact on its financials or operations. This development marks progress in resolving a long-standing litigation matter from over a decade ago.

NFAC passed an order on February 13, 2026, directing the Assessing Officer to allow relief to the company.
The dispute relates to Assessment Year 2012-13 and an appeal filed by Syngene on January 21, 2020.
The original order dated December 23, 2019, had disallowed certain business expenses under the Income-tax Act.
The company expects no material financial impact following the verification by the Assessing Officer.
The order was passed under Section 250 of the Income-tax Act, 1961.

💡 This is a positive but non-material legal update regarding legacy tax matters. No immediate action is required as it does not significantly alter the company's valuation or earnings outlook.

Syngene to Meet Institutional Investors at Axis Capital Conference on Feb 10-11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Feb 2026, 06:50 PM

Syngene International Limited has scheduled physical one-to-one meetings with analysts and institutional investors in Mumbai. The company will participate in the Advantage India - Axis Capital's Flagship India Conference on February 11, 2026. Additionally, several short-notice meetings are planned for February 10, 2026. The management has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Participation in Axis Capital's Flagship India Conference on February 11, 2026
One-to-one physical meetings scheduled for February 10 and 11 in Mumbai
Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed
Meetings arranged pursuant to Regulation 30 of SEBI Listing Obligations

💡 This is a routine disclosure with no immediate impact on stock valuation. Investors should look for any subsequent investor presentations uploaded to the exchange for updates on business strategy.

Syngene International Releases Q3 FY2026 Earnings Call Transcript

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Jan 2026, 05:50 PM

Syngene International has published the official transcript for its Q3 FY2026 earnings conference call, which was originally held on January 23, 2026. This filing is a standard regulatory requirement under SEBI's Listing Obligations and Disclosure Requirements. The transcript provides a detailed record of management's responses to institutional investor queries regarding the company's financial health and strategic direction. Investors can access the full text via the company's website to review qualitative insights into the quarter's performance.

Earnings call for the third quarter of FY2026 was conducted on January 23, 2026.
Official transcript was formally filed with the exchanges on January 29, 2026.
The document is accessible via the company's investor relations portal on their website.
Filing complies with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should review the transcript for management's outlook on the CRO/CDMO sector and specific guidance for the upcoming quarters. No immediate action is required as this is a routine administrative disclosure.

Syngene Schedules One-on-One Virtual Meeting with Skerryvore Asset Management

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Jan 2026, 05:44 PM

Syngene International Limited has announced a scheduled interaction with Skerryvore Asset Management on February 4, 2026. The meeting is set to take place virtually at 3:30 PM IST as a one-on-one session. This disclosure is a routine filing under Regulation 30 of SEBI (LODR) Regulations, 2015. The company has confirmed that no unpublished price sensitive information (UPSI) will be shared during the discussion.

Meeting scheduled with Skerryvore Asset Management on February 4, 2026
The interaction will be a virtual one-to-one meeting starting at 3:30 PM IST
Company explicitly stated that no UPSI will be disclosed during the session
Filing made in compliance with SEBI Listing Obligations and Disclosure Requirements

💡 No immediate action is required as this is a routine investor relations activity. Investors may check the company website later for any presentation materials or transcripts shared after the meeting.

Syngene to Hold One-on-One Meeting with J.P. Morgan Asset Management on Feb 2

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Jan 2026, 06:58 PM

Syngene International Limited has scheduled a virtual one-on-one meeting with J.P. Morgan Asset Management on February 2, 2026, at 4:30 PM IST. This interaction is part of the company's regular engagement with institutional investors to discuss business performance and outlook. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during this meeting. Such disclosures are mandatory under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

One-on-one virtual meeting scheduled with J.P. Morgan Asset Management.
The meeting is set for February 2, 2026, at 4:30 PM IST.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
The notification was filed on January 28, 2026, in compliance with SEBI Regulation 30.

💡 This is a routine regulatory filing for an investor meeting. No immediate action is required, but investors may check the company website later for any post-meeting presentations or transcripts.

Syngene International Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Jan 2026, 05:12 PM

Syngene International has officially released the audio recording of its Q3 FY26 earnings conference call held on January 23, 2026. This disclosure is a routine regulatory requirement under Regulation 30 of the SEBI Listing Regulations to ensure transparency. The recording provides investors with direct access to management's commentary regarding the company's financial performance and strategic direction for the quarter. Shareholders can access the audio file via the link provided in the company's official filing.

Audio recording of the Q3 FY26 earnings call conducted on January 23, 2026, is now available.
The filing is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Recording link: https://cdn.syngeneintl.com/2026/01/23214135/10039244.mp3.
Provides transparency into management's discussion on quarterly financial results.

💡 Investors should listen to the recording to understand management's guidance on revenue growth and margin sustainability. No immediate trading action is required based on this procedural filing.

Syngene Q3 FY26: PAT Drops 44% YoY to ₹73 Cr; BMS Partnership Extended to 2035

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 12:24 PM

Syngene International reported a weak set of numbers for Q3 FY26, with revenue from operations declining 3% YoY to ₹917 crore. Profitability was significantly impacted as Reported PAT (before exceptional items) fell 44% YoY to ₹73 crore, and Operating EBITDA margins contracted to 23% from 30% in the year-ago period. On a strategic note, the company secured a long-term extension of its Bristol Myers Squibb (BMS) partnership through 2035, providing long-term revenue visibility. For the nine-month period (9M FY26), revenue grew marginally by 3% while PAT declined by 22%.

Q3 FY26 revenue from operations stood at ₹917 crore, a 3% decline compared to ₹946 crore in Q3 FY25.
Reported PAT for the quarter fell sharply by 44% YoY to ₹73 crore, down from ₹130 crore in the previous year.
Operating EBITDA margin contracted to 23% in Q3 FY26, significantly lower than the 30% reported in Q3 FY25.
Strategic extension of the Bristol Myers Squibb (BMS) partnership through 2035, expanding the scope of integrated services.
Total single-use bioreactor capacity reached 50,000L following the acquisition of the Baltimore, USA site.

💡 Investors should be cautious due to the sharp margin contraction and PAT decline, which indicate near-term operational headwinds. However, the 10-year extension of the BMS contract and ongoing capacity expansions in the US and India offer long-term structural support.

View All SYNGENE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Research Services contributed 61% of total revenue in FY25 and remained stable, while Large Molecule Development and Manufacturing grew 22% YoY, increasing its revenue share from 21% in FY24 to 25% in FY25. Discovery Services saw slower growth due to a challenging US Biotech funding environment.

Geographic Revenue Split

98% of total revenues are derived from overseas markets, with the US market alone accounting for 61% of FY25 revenues. Other key regions include Europe and Japan.

Profitability Margins

Reported PAT margin for Q2 FY26 was 7% (INR 67 Cr), a significant decline from the previous year. FY25 PAT before exceptional items was INR 474.9 Cr, down 8% YoY from INR 518.6 Cr in FY24.

EBITDA Margin

Operating EBITDA margin for H1 FY26 stood at 23%, down from 25% in H1 FY25. FY25 EBITDA margin was 28.6% (INR 1,113.6 Cr) compared to 29.1% in FY24.

Capital Expenditure

Annual organic capex is planned at INR 500-600 Cr. Q2 FY26 capex was $10 million (approx. INR 84 Cr), with 50% allocated to research services (DMPK automation, ADC labs) and 30% to CDMO facilities in Bangalore and the US.

Credit Rating & Borrowing

ICRA reaffirmed [ICRA]AA+ (Stable) for long-term ratings and [ICRA]A1+ for short-term facilities totaling INR 1,500 Cr. Adjusted gearing is exceptionally low at 0.03 times as of March 31, 2025.

⚙️ Operational Drivers

Raw Materials

Costs of chemicals, reagents, and consumables consumed represented 26.2% of revenue in Q2 FY26, totaling INR 238.5 Cr.

Import Sources

Not explicitly disclosed by country, but the company is developing a diversified supplier network to reduce dependency on high-cost suppliers.

Capacity Expansion

Acquired a Biologics manufacturing facility in Baltimore, USA (operational by Dec 2025) and another facility (Stelis Unit 3) in Bangalore to drive Large Molecule growth.

Raw Material Costs

Raw material costs in FY25 were INR 942.5 Cr, a 1% increase YoY. The company expects full-year raw material costs to stabilize around 25% of revenue.

Manufacturing Efficiency

Focus on 'level of productivity' to match 'China switcher' expectations; utilizing AI tools for process simplification and delivery turnaround time.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Achieving growth through the '1-3-5 plan' focusing on Large Molecule CDMO, operationalizing the Baltimore facility by Dec 2025, and expanding SynVent Integrated Drug Discovery (IDD) services. The company is also targeting 'China switchers'—clients moving supply chains away from China.

Products & Services

Contract research (CRO), discovery services (DMPK, ADC labs), biologics manufacturing (Large Molecule CDMO), small molecule CDMO, and payload/linker manufacturing.

Brand Portfolio

Syngene, SynVent, SynVent IDD.

New Products/Services

New capabilities in Antibody-Drug Conjugates (ADC) labs and payload/linker manufacturing to complement existing commercial capabilities.

Market Expansion

Expanding commercial teams closer to client locations in North America, Europe, and Japan; new manufacturing presence in Baltimore, USA.

Market Share & Ranking

Not disclosed in percentage terms, but noted as a leading player in the Indian contract research space.

Strategic Alliances

Maintains dedicated research centers for major clients and strategic marketing focused on high-value key account management.

🌍 External Factors

Industry Trends

The industry is shifting toward Large Molecule/Biologics CDMO; Syngene is positioning itself by increasing Biologics revenue share to 25%.

Competitive Landscape

Faces competition from global CROs, domestic players, and captive R&D centers of large pharma companies.

Competitive Moat

Moat built on high-end scientific talent, robust compliance/safety records (EcoVadis score 74/100), and long-term integrated contracts that create high switching costs.

Macro Economic Sensitivity

Highly sensitive to US Biotech funding cycles and global pharmaceutical R&D spending trends.

Consumer Behavior

Increased preference for 'one-stop-shop' providers that can handle both discovery and commercial-scale manufacturing.

Geopolitical Risks

Exposure to US-China trade shifts (China switchers) provides an opportunity, while 61% revenue concentration in the US poses a geographic risk.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to pharma regulatory approvals and clinical trial regulations; implementing digital tracking for licenses and permits.

Environmental Compliance

Earned 'Green Certification' from My Green Lab with a score >94%; EcoVadis 2025 score rose to 74/100 (91st percentile).

Taxation Policy Impact

Tax expense increased 35% YoY to INR 153 Cr in FY25. The company adopts a litigation strategy for ongoing tax cases with expert advisors.

Legal Contingencies

Ongoing tax disputes and contractual management risks are monitored by an executive-level committee; specific INR values for pending litigations not disclosed.